Drugs / FluLaval® Tetra
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT02831751 Comparator | Apr → Jul 2016 | primary viral infectious disease, respiratory tract infectious disorder | Medicago | Completed | No outcome recorded |
| Phase 2 | NCT02768805 Comparator | Mar → May 2016 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FluLaval Tetra | “15 µg/strain of the licensed and commercially available quadrivalent vaccine FluLaval® Tetra” NCT02768805 ↗ |
| Modality | Vaccine | “licensed and commercially available quadrivalent vaccine FluLaval® Tetra” NCT02768805 ↗ |